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Abstract
Background: Despite significant advances in unravelling the pathophysiology of cluster headache (CH), little is known
about neuropsychological functioning. Apart from neuroimaging studies indicating involvement of posterior hypothalamic
and other areas frequently involved in nociception, some studies suggest involvement of prefrontal areas. Among others,
these mediate executive functioning (EF).
Methods: Therefore, three neuropsychological tests (Trail Making Test (TMT), Go/Nogo Task and Stroop Task) were
completed by four headache patient samples (chronic CH, episodic CH in the active or inactive period, and migraine
patients) and compared to healthy controls.
Results: Analyses revealed that patients especially with chronic and active episodic CH were particularly impaired in tests
relying more on intact EF (i.e. TMT-B, Stroop interference) than on basal cognitive processes (i.e. TMT-A, Stroop
naming). Within the CH groups performance decreased linearly with increasing severity.
Discussion: These findings are in line with a recently proposed involvement of prefrontal structures in CH pathophysi-
ology as patients performed worse on neuropsychological tasks relying on these structures. Impaired EF could also result
from medication and sleep disturbances due to active CH. Because the decreased performance was also present outside
the attacks it may hint at generally altered brain functions, but do not necessarily reflect clinically relevant behaviour.
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Introduction
Cluster headache (CH) is characterized by recurring
tormenting pain attacks (1) that impair a patient’s func-
tioning and quality of life to a great extent (2,3). Recent
studies on various aspects of impairment indicate that
CH patients are severely impaired in economic as well
as non-economic domains and seem to be more vulner-
able to diverse psychiatric co-morbidities (4) with
depression as a prevalent condition (5). Because CH
pathology has also been associated with behavioural
alterations (6), diﬀerences in more complex cognitive
functions involving coordination, regulation and inhib-
ition of behaviour are conceivable.
Neuroimaging studies in CH found morphological
and functional changes in the posterior inferior
hypothalamus (PIH) suggesting a key role in its
pathophysiology (7), consistent with changes in
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neuroendocrinology reported in CH and good eﬃcacy
of hypothalamic deep brain stimulation in refractory
CH (8). These data support a link between the PIH
and the trigeminovascular system by nociceptive
hypothalamo-trigeminal and hypothalamo-autonomic
pathways. Little is known about connections to other
regions such as the prefrontal cortex (PFC) via dopa-
minergic midbrain cells. Both PIH and PFC are part of
a motivation circuit mainly involved in executive func-
tion (EF), impulse control and decision making (9).
Interestingly, a study investigating episodic CH patients
found a glucose hypometabolism in prefrontal struc-
tures both inside and outside the active period CH
(10). Likewise, a study using visually-evoked event-
related potentials (ERP) found increased latencies in
CH patients that were interpreted as aberrancies in pre-
frontal brain areas (11).
So far, little is known about functional eﬀects of
prefrontal involvement on neuropsychological out-
comes in CH such as EF (12). Impaired EF has been
suggested for a variety of chronic pain conditions
(13,14), highlighting the association of pain syndromes
with altered neuroplasticity and dysregulated neuro-
chemistry in the PFC.
Whereas a general cognitive impairment in migraine
and CH may be best seen during acute headache while
wearing oﬀ interictally (15), data on speciﬁc functions
such as memory, attention or EF are scarce. One study
assessed verbal memory and EF in active episodic CH
(ECH) and reported only decreased auditory verbal
memory as compared with tension headache patients
(16), an impairment that could also be shown in
migraine patients (17). As pain may interfere with cog-
nitive performance (18), it is unclear whether pain itself
(15) or the underlying headache pathology results in
decreased test scores. It is not known either whether
diﬀerences exist between the diﬀerent subtypes of CH
(such as episodic and chronic CH).
In this study we hence aimed to determine whether
there are speciﬁc diﬀerences between clinically import-
ant subgroups of CH in three neuropsychological tests
designed for assessing monitoring, response inhibition
and cognitive control (19–22), three important factors
of EF (23). Successful performance in these tests
requires the integrity of associated neuronal networks,
especially prefrontal cortical areas (24–27).
Methods
Participants
Headache patients were recruited at the Departments of
Neurology, University Hospitals of Regensburg and
Halle, and at the Kiel Headache Centre as part of a
larger study on diﬀerent facets of cluster headache
(4,28). Patients were diagnosed according to the
ICHD-II criteria for migraine without and with aura
(IHS 1.1 and 1.2) and for episodic and chronic cluster
headache (IHS 3.1.1 and 3.1.2) by an experienced head-
ache specialist (29). Ninety-seven headache patients
were included, 27 patients with chronic cluster head-
ache (CCH), 26 with episodic cluster headache in the
active period (ECHa), 22 with episodic cluster headache
outside the active period (ECHi) and 24 patients with
migraine (MIG). Additionally 31 healthy controls (HC)
were recruited in the respective centres. Groups were
comparable in age, patients were comparable in age
of headache onset and duration of headache (for all
tests: p> 0.12). Patients in the ECH groups were allo-
cated to one subgroup only and not examined twice
(independent samples). Detailed data on the sample
can be found elsewhere (4). All participants ﬁlled in
the German version of the ‘Alcohol Use Disorders
Identiﬁcation Test’ (AUDIT) (30), a screening ques-
tionnaire to identify harmful drinking. All subjects
gave written informed consent. The study was
approved by the lead ethics committee of the
University of Regensburg as well as the local ethic com-
mittees and was in compliance with the Declaration of
Helsinki from 2008.
Neuropsychological tests
Neuropsychological testing included the Trail Making
Test (TMT), the Go/Nogo Task and the Stroop Task.
These tasks involve assessing the integrity of diﬀerent
neuropsychological functions, such as cognitive ﬂexibil-
ity, monitoring, response inhibition and response exe-
cution, and cognitive control.
Trail Making Test (TMT). The TMT (31) consists of two
conditions: the TMT-A requires participants to draw
lines to connect, in order, circled numbers from 1
to 25 positioned randomly on a sheet of paper; the
TMT-B requires participants to alternate between num-
bers and letters (e.g. 1 – A – 2 – B – 3 –. . .). The pro-
cessing time was measured in both TMT conditions.
The TMT-B condition utilizes cognitive ﬂexibility
while switching between two tasks (numbers and let-
ters), thus assessing monitoring (32). This is an import-
ant neuropsychological function that enables quick
adoption of changing task requirements.
Go/Nogo Task. In the Go/Nogo Task, taken from a stan-
dardized attention test battery (33), participants have
to respond to a Go stimulus while inhibiting the
response to a Nogo stimulus. Median reaction time
and standard deviation for Go trials and number of
commission (responding in Nogo trials) and omission
errors (non-responding in Go trials) were used as
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dependent variables. The Go/Nogo Task requires the
suppression of an already prepared motor response,
thus measuring response inhibition (34). This test
involves both processes of response inhibition and
response execution, thereby requiring higher-order
motor and attention control.
Stroop Task (colour-word interference). Cognitive control
was measured by the Stroop Task (35), a well-
established neuropsychological tool (22). The German
version (21) was used with the subtests reading, naming
and interference. The interference condition necessi-
tates selective turning towards a speciﬁc target feature
(naming the colour) and control of automatic processes
(reading the incongruent word). The time in colour
reading, colour naming and interference, as well
as two regression-corrected indices (nomination and
selectivity) were used for statistical analyses.
Nomination is an index for naming speed, corrected
for reading speed (21). Selectivity is an index for con-
centrative resistance against dominating, automated
response tendencies (reading), corrected for naming
speed (21). Values above/below 100 indicate a
shorter/longer RT than might be expected. This task
requires the successful voluntary inhibition of involun-
tary automatic processes, an important facet of cogni-
tive control.
Data analysis
Data were tested for normal distribution using the
Kolmogorov–Smirnov test and analysed by means of
analyses of variance (ANOVA) and post hoc t-tests
(SPSS 18). If a normal distribution could not be
ascertained, a non-parametric analysis (Kruskal–
Wallis test, Mann–Whitney U-test) was additionally
conducted to check if they yielded identical results
as the parametric tests. Non-parametric analyses will
only be reported in case of divergence. If the
assumption of sphericity was violated as shown in
the Mauchly’s test (p< 0.10), degrees of freedom
were corrected according to Greenhouse–Geisser.
When a condition was varied within a task, a uni-
variate two-way (condition group) ANOVA was
performed. Interaction eﬀects were further disen-
tangled by univariate one-way ANOVAs and t-tests
within the condition factor’s levels. Bonferroni’s cor-
rection was used to account for the accumulation of
the alpha error; uncorrected p-values are given
whenever necessary. Error data in the Go/Nogo
task were analysed by non-parametric tests through-
out. Alpha level was set to 5%; all tests were two-
tailed. Because of missing data for some patients in
the neuropsychological tests the number of subjects
within a group can be smaller than written above
(see Table 1).
Table 1. Descriptive statistics and results of the univariate analyses for the neuropsychological variables.
Variable CCH ECHa ECHi MIG Control p-value
Trail-Making Test n¼ 24 n¼ 26 n¼ 18 n¼ 23 n¼ 31
TMT-A 30.67 9.17 29.50 12.29 26.06 5.76 25.74 10.51 24.10 8.76 <0.001
TMT-B 89.96 36.60 76.38 32.63 61.11 15.33 57.87 21.11 51.35 13.83 <0.001
Go/Nogo Task n¼ 27 n¼ 26 n¼ 21 n¼ 22 n¼ 31
Commission errors 2.15 3.76 1.27 2.95 1.19 3.93 0.64 1.53 0.61 1.02 0.148a
Omission errors 1.04 2.36 0.50 1.42 0.81 2.64 0.55 2.56 0.00 0.00 0.006a
Go-RT 572.24 90.34 557.37 93.57 529.24 54.47 529.89 77.31 499.82 74.05 0.010
SD Go-RT 94.27 37.60 82.66 36.81 75.78 21.79 77.47 23.90 68.37 25.45 0.027
Stroop Task n¼ 26 n¼ 25 n¼ 21 n¼ 23 n¼ 31
Stroop reading 32.96 5.86 30.92 4.81 30.38 4.18 29.09 4.65 28.29 4.76 0.008
Stroop naming 48.85 7.15 47.56 10.62 45.29 9.27 45.13 7.90 41.13 5.91 0.007
Stroop interference 83.50 16.03 78.84 20.81 72.76 13.83 74.39 12.96 65.65 11.40 <0.001
Stroop nomination 101.73 7.41 100.80 6.78 102.24 7.01 100.04 5.72 102.68 5.77 0.610
Stroop selectivity 100.35 6.73 101.48 5.49 102.19 5.90 100.74 6.54 101.68 4.13 0.810
Mean values and standard deviations are given.
aKruskal–Wallis H-test, in all other variables one-way ANOVAs were used.
CCH: chronic cluster headache; ECHa: episodic cluster headache in the active period; ECHi: episodic cluster headache outside the active period;
MIG: migraine; Control: healthy controls.
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Results
Trail-Making Test (see Figure 1)
The 2 5 ANOVA with the factors condition (TMT-A,
TMT-B) and group (CCH, ECHa, ECHi, M, HC)
revealed a signiﬁcant main eﬀect for condition
(F1, 117¼ 367.677, p< 0.001) and group (F4, 117¼ 8.791,
p< 0.001), and a signiﬁcant condition-by-group inter-
action (F4, 117¼ 8.236, p< 0.001). The eﬀect condition
reﬂects the higher diﬃculty of the TMT-B with substan-
tially increased response latencies apparent in all
groups. The interaction was due to a diﬀerential eﬀect
of the groups within the two conditions. Post hoc one-
way ANOVAs within the two conditions with the
factor group revealed that only for the TMT-B the
group factor was signiﬁcant (F4, 117¼ 9.527, p< 0.001).
In the TMT-B, the CCH group diﬀered signiﬁcantly
from the ECHi, MIG and HC group (all Bonferroni-
corrected p< 0.005), but not from the ECHa group,
which also diﬀered from the HC group (p¼ 0.004).
Descriptive statistics are given in Table 1.
Go/Nogo Task (see Figure 2)
The Kruskal–Wallis H-test did not reveal a signiﬁcant
eﬀect for the commission errors (4
2¼ 6.788,
p¼ 0.148), that would have indicated an impulsive or
disinhibited reaction, but only for omission errors
(24¼ 14.453, p¼ 0.006). That was due to more omis-
sion errors in all three CH groups as compared to the
controls (Mann–Whitney U-tests: p< 0.05). For the
reaction time data a signiﬁcant eﬀect of group was
found in the ANOVA for the median reaction time
(i.e. decision speed, F4, 122¼ 3.499, p¼ 0.010), which
was due to a signiﬁcantly increased reaction time
for the CCH compared to the HC group (Bonferroni-
corrected p¼ 0.008). At an uncorrected level also
ECHa diﬀered from the HC group (p< 0.01). For the
standard deviation of the individual reaction times a
signiﬁcant group eﬀect emerged (F4, 122¼ 2.835,
p¼ 0.027), which was also due to a signiﬁcant increase
in the CCH compared to the HC group (p< 0.05).
At an uncorrected level CCH also diﬀered from the
ECHi group (p< 0.05). Descriptive statistics are given
in Table 1.
Stroop Task (see Figure 3)
For the Stroop interference task the 3 5 ANOVA
with the factors condition (reading, naming, interfer-
ence) and group revealed a signiﬁcant main eﬀect for
condition (F1.3, 157.6¼ 1143.148, p< 0.001) and group
(F4, 121¼ 5.651, p< 0.001), and a signiﬁcant interaction
condition-by-group (F5.2, 157.6¼ 3.582, p¼ 0.004). The
interaction eﬀect was due to a larger group eﬀect in
the interference than in the other two conditions as
two-way ANOVAs with two conditions were only sig-
niﬁcant when the interference condition was included
(F4, 121> 3.907, p< 0.01), but not for the remaining two
conditions (reading, naming; F4, 121¼ 1.404, p¼ 0.237).
Descriptive statistics are given in Table 1.
One-way ANOVAs within each condition revealed a
signiﬁcant group eﬀect for all three conditions: reading
(F4, 121¼ 3.656, p< 0.01), naming (F4, 121¼ 3.696,
p< 0.01), and interference (F4, 121¼ 5.428, p< 0.001).
In all conditions the Bonferroni-corrected post hoc
tests revealed that the CCH group showed signiﬁcantly
increased response latencies as compared to the HC
group; in naming and interference the ECHa group
also showed signiﬁcantly increased response latencies.
At an uncorrected level MIG patients had an increased
interference (p¼ 0.04) and naming time (p¼ 0.08) as
compared to controls
The two additional indices derived from the data
(21), i.e. nomination (corrected nomination speed)
and selectivity score (corrected interference score) did
not reveal any diﬀerences between the groups.
To investigate neuropsychological functioning within
the three CH groups, we set up linear polynomial con-
trasts (i.e.1 0 1) for each of the indices assuming linear
eﬀects from ECHi over ECHa to CCH. These were sig-
niﬁcant for the TMT-B and the Stroop interference
(all t> 2.115; p< 0.05). These tests indicate increased
EF impairment with more severe CH (see Figures 1–3).
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Figure 1. Mean processing time in the Trail-Making Test
(TMT-A and TMT-B). Error bars indicate standard errors of the
mean. CCH: chronic cluster headache; ECHa: episodic cluster
headache in the active period; ECHi: episodic cluster headache
outside the active period; MIG: migraine; Control: healthy controls.
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Investigation of potential confounds
To elucidate the inﬂuence of potential confounds on the
neuropsychological variables, inﬂuence of medication,
attack frequency, self-reported lifetime depression,
circadian timing of attacks and alcohol consumption
were investigated.
Various prophylactics (i.e. verapamil, lithium, gaba-
pentin, topiramate, valproic acid and beta-blockers)
were taken by 22 CCH patients, 17 ECHa patients,
5 ECHi patients and 6 migraine patients (see Table 2
for further details).
Within the CH groups, taking prophylactic medica-
tion hardly inﬂuenced neuropsychological performance.
Although patients with ECHi taking prophylactic medi-
cation (n¼ 5) performed worse in the TMT-A and
TMT-B (Mann–Whitney U-test: p¼ 0.019/0.063),
results did not diﬀer signiﬁcantly in the other groups.
In the combined group of CH patients there was no
signiﬁcant association of the neuropsychological vari-
ables with attack frequency, days on which acute medi-
cation is taken per month and amount of daily acute
medication (Spearman’s r, all p> 0.05, uncorrected).
In the combined group of CH patients, patients
reporting lifetime depressive symptoms showed
increased GoNogo reaction time and standard devi-
ation (t> 2.74, p< 0.05) when compared with patients
who did not report such symptoms. As distribution of
self-reported lifetime depressive symptoms was just
equally distributed (2¼ 4.50, p¼ 0.11), additional
exploratory analysis revealed that within the groups
no consistent patterns could be conﬁrmed.
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Figure 2. Median reaction time, standard deviation (upper panels), commission and omission errors (lower panels) in the Go/Nogo
Task. Error bars indicate standard errors of the mean.
CCH: chronic cluster headache; ECHa: episodic cluster headache in the active period; ECHi: episodic cluster headache outside the
active period; MIG: migraine; Control: healthy controls.
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Figure 3. Mean time needed for the subtests colour reading,
colour naming and interference in the Stroop Task (colour-word
interference) as compared to healthy controls. Error bars indi-
cate standard errors of the mean.
CCH: chronic cluster headache; ECHa: episodic cluster headache
in the active period; ECHi: episodic cluster headache outside the
active period; MIG: migraine.
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When patients with daily attacks were contrasted
with patients with nocturnal or both daily and noctur-
nal attacks to exclude sleep deprivation as a confoun-
der, no signiﬁcant diﬀerence was found.
As excessive alcohol consumption is associated with
deﬁcits in executive functions (e.g. (36,37)), diﬀerences
in alcohol use might have inﬂuenced the results. We
reanalysed the data using the presence of hazardous
drinking as detected with the AUDIT (deﬁned by a
threshold sum score of 5). Results for the primary EF
variables were not changed.
Taken together, no consistent patterns were found
that indicate a substantial inﬂuence of putative con-
founds on the neuropsychological variables.
Discussion
In the present study neuropsychological functioning in
CH was investigated and the results showed that
chronic CH and episodic CH patients in the active
period were particularly impaired in tests relying
more on intact executive function than on basal cogni-
tive processes.
Neuropsychological functioning in CH
In all neuropsychological measures (Trail-Making Test,
Go/Nogo Task and Stroop Task) the analyses yielded
signiﬁcant eﬀects indicating meaningful group diﬀer-
ences between patients with CH, migraine and healthy
controls. Post hoc tests revealed that the diﬀerences
were mainly driven by the CCH group performing
worse as compared to the controls. The results also
revealed a pattern of worse performance with increas-
ing severity of CH, as the performance scores were
arranged in the order CCH>ECHa>ECHi. Such a
pattern could be seen in almost every variable, even
when the analysis failed to reach signiﬁcance.
Hence, across diﬀerent presentations of CH, CCH in
particular was associated with decreased performance.
Interestingly, and in line with our hypotheses, the
eﬀects were more pronounced for subtests that mainly
rely on EF, respectively monitoring and cognitive con-
trol, demanding increased cognitive capacity such as
the TMT-B or the Stroop interference condition,
whereas more basic cognitive tasks (TMT-A, Stroop
reading, Stroop naming) were performed more equally
(see Figures 1 and 3). For the nomination and selectiv-
ity scores in the Stroop Task, i.e. scores corrected for
reading and naming speed, respectively, no signiﬁcant
group diﬀerences emerged. This may indicate that even
basic processes necessary for complex EF could be
aﬀected. However, as these scores are scarcely reported
and only established in German samples, the generaliz-
ability of these results remains preliminary and warrant
further investigation. The uncorrected processing time
in the interference condition – normally used as a meas-
ure for EF in other studies – indicates decreased per-
formance in cognitive control in the CCH patients.
There is a need to discuss why the EF index in the
Go/Nogo task (i.e. commission errors as usual indica-
tor of response inhibition) did not diﬀer between the
groups, whereas an increased response time in the Go
condition and an increased number of omission errors
were found in the CCH patients. This may point
towards an increased response inhibition. It is feasible
that – while monitoring (TMT-B) and cognitive control
(Stroop) is impaired – patients tend to respond more
carefully in tasks measuring impulsivity/inhibition to
avoid making mistakes. That is, they prefer responding
more slowly and omitting a response than committing a
wrong response. This corresponds with the ﬁnding that
CH patients are aware of their condition and the result-
ing impairment (4).
Data on neuropsychological characteristics of
patients with CH are scarce. Jorge et al. (16) found
decreased verbal memory scores in ECHa patients,
which the authors assumed to be the result of a puta-
tively impaired left medial temporal network function.
However, they did not report diﬀerences in EF, which
yet might be due to the included tests (Rey Complex
Figure Test, Tower of Toronto, Oral Word Association
Test) and to a control group of tension headache
patients – which might underestimate a decrease in per-
formance. Besides, CCH patients – the group perform-
ing worst in the present study – were not studied.
Imaging studies rather hint towards a prefrontal
involvement in the pathophysiology of CH (1,10,11).
Likewise, in our study altered interictal responses in
prefrontal brain function resulting in impaired test
results could be assumed a priori. In line with a previ-
ous imaging study (10) that found hypometabolism in
CH inside, but also outside the bout, CH patients per-
formed poorly in tasks strongly relying on these pre-
frontal structures. Given this, the neuropsychological
proﬁle found in this study (i.e. CH patients display a
Table 2. Preventative drugs used by patients
Variable CCH ECHa ECHi MIG
n¼ 27 n¼ 26 n¼ 22 n¼ 24
Verapamil 18 (67%) 15 (58%) 4 (18%) 0
Lithium 4 (15%) 5 (19%) 0 3 (13%)
Topiramate 2 (7%) 1 (4%) 1 (5%) 0
Gabapentin 0 1 (4%) 0 0
Beta-blocker 1 (4%) 0 0 3 (13%)
CCH: chronic cluster headache; ECHa: episodic cluster headache in the
active period; ECHi: episodic cluster headache outside the active period;
MIG: migraine.
818 Cephalalgia 32(11)
decreased neuropsychological performance) ﬁts well
with the underlying reported neurometabolical
changes. This is a pathophysiologically relevant issue
that has not been addressed before. The decreased per-
formance does not imply that it interferes with normal
daily activities, as these tests assess more subtle neuro-
psychological dysfunction. A detailed analysis of the
relation between subtle cognitive eﬀects and selective
inﬂuences in quality of life would overemphasize the
results of this study. For tests assessing more severe
cognitive impairment with ceiling eﬀects (such as the
Mini Mental State Examination) decreased perform-
ance in CH patients seems to be only apparent during
headache episodes, but not in between (15). Due to the
excruciating nature of the CH attacks, neuropsycho-
logical assessment during attacks is not feasible. Thus,
neuropsychological tests measuring EF should be used
interictally to assess a possible prefrontal impairment.
As one study found, executive dysfunction may predict
the formation of psychiatric symptoms (38) which are
frequent in patients with CH (4) and thus in the future a
well-chosen test battery may represent a tool to detect
patients at risk at an early stage. However, up to now,
these considerations are speculative and to draw valid
conclusions more longitudinal data are needed. Also,
the reported study (38) only investigated psychiatric
inpatients, thereby limiting the generalizability of the
results.
Neuropsychological functioning in migraine
patients
Migraine patients did not substantially diﬀer from
the healthy controls in our examination; only a
worse performance in Stroop interference emerged
at an uncorrected alpha level. So far, neuropsy-
chological ﬁndings in migraine patients are not
conclusive. Whereas some studies found worse per-
formance (especially in memory), others did not (for
a review see (39)). The largest eﬀects were found
for the CCH and ECHa groups, further supporting
the headache severity in these groups. These results
are hence in line with a recent review article
that found only weak or inconclusive evidence for
impaired neuropsychological functioning in migraine
patients (40).
Neuropsychological function in painful conditions
Pain experience, itself resulting in decreased neuro-
psychological performance, might oﬀer an explan-
ation at ﬁrst sight, as such eﬀects have been found
in pain challenges in healthy controls (18). Yet these
studies focus more on the impact of acute pain
rather than chronic pain present for years. It is
therefore unlikely that results can be explained
by experience of pain itself rather than a speciﬁc
eﬀect of CH.
Limitations
Although we aimed to control for the potential con-
founders ‘medication’ and ‘sleep disturbance’, we actu-
ally cannot rule out an inﬂuence of these factors. The
percentage of patients taking prophylactic medication
in the CCH and ECHa groups was higher than in the
ECHi group, which might have inﬂuenced the results.
We also did not directly assess sleep disturbances by
use of a sleep diary, somnography or direct interroga-
tion but relied on information about the timing of
attacks. More homogeneous groups would have been
needed to exclude or control for cognitive eﬀects of
each preventative drug as relevant confounder. Studies
on cognitive eﬀects of verapamil (41) and topiramate
(42) are sparse and do not allow any comparison with
data presented in this study. Although the factors
‘medication’ and ‘sleep disturbance’ did not show
any relevant eﬀect on EF, more appropriate variables
are necessary to fully examine these complex relation-
ships. In future studies longitudinal designs should
additionally be considered to better elucidate such
eﬀects.
One limitation of the present study is a sample size
of about 20 to 25 subjects per group, which restricts the
validity of extensive correlation analyses. Larger studies
will help to ﬁnd possible associations of the neuropsy-
chological performance with other variables more
reliably. However, this is the ﬁrst study with well-
characterized headache patients including the clinically
relevant subgroups of CH totalling almost 100 patients.
The additional use of neuroimaging methods would
have helped to further corroborate the interaction
between neuropsychological functioning and underly-
ing pathophysiology.
As only self-reported symptoms of lifetime depres-
sion were recorded, confounding eﬀects of acute
depressive symptoms were not assessed. In add-
ition, the number of depressive episodes should be rec-
orded in future studies, as neuropsychological
performance decreases with increasing number of epi-
sodes (43).
We cannot rule out that the selection of neuropsy-
chological tests may have inﬂuenced the results, as
other tests might have been more sensitive (e.g.
memory tests as in (16)). However, derived from
recent imaging data in CH, the applied tests seem to
map the neural alterations best.
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Conclusion
Our data suggest prefrontal alterations in patients with
CH that are reﬂected in the performance in neuropsy-
chological tasks measuring EF and are in line with
recent neuroimaging studies. Because the decreased
performance was present outside the attacks it may
hint at generally altered brain functions. Although
these changes do not necessarily reﬂect clinically rele-
vant behaviour, they contribute to a better understand-
ing of CH pathophysiology.
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